Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled multicentre trial of memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies.

Trial Profile

A double-blind, placebo-controlled multicentre trial of memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Memantine (Primary)
  • Indications Dementia; Lewy body disease; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms MEMPDD

Most Recent Events

  • 09 Feb 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record. (1 Feb 2008)
  • 25 Apr 2015 Pooled analysis results of this trial and other two 24-Week , placebo-controlled trials presented at the 67th Annual Meeting of the American Academy of Neurology.
  • 17 Jul 2013 Secondary endpoint (Clinical Dementia Rating) results presented at the 2013 Alzheimer's Association International Conference .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top